市場調査レポート
商品コード
1464051

バイオロジクスCDMOの世界市場レポート 2024年

Biologics CDMO Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円
バイオロジクスCDMOの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

バイオロジクスCDMO市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR14.4%で365億4,000万米ドルに成長します。予測期間の成長は、生物学的製剤に対する需要の増加、バイオシミラーやバイオベターの出現、バイオ製造インフラへの投資、複雑なプロセスのアウトソーシングへのシフト、サプライチェーンの回復力とリスク軽減への注目の高まり、規制の調和、承認の迅速化など、いくつかの要因に起因すると考えられます。この期間に予想される主な動向には、エンド・ツー・エンドのソリューションを提供する能力の拡大、シングルユース技術の採用、連続製造プロセスの統合、専門CDMOの出現などが含まれます。

細胞治療と遺伝子治療に対する需要の高まりは、当面、生物学的製剤の開発・製造受託機関(CDMO)市場の拡大を牽引する見通しです。細胞療法と遺伝子療法は、生きた細胞や遺伝物質を利用し、細胞や遺伝子レベルで根本的な疾病メカニズムを標的とする最先端の医療手法であり、従来の医薬品では管理が困難であったり治癒が困難であったりする疾患に対する潜在的な治療法を提供するものです。細胞治療や遺伝子治療の需要が高まっているのは、根本的な遺伝的・細胞的原因に対処することで、疾患に対する革新的な治療法を提供できる可能性があるからです。バイオロジクスCDMOは生きた細胞、ウイルスベクター、遺伝物質の取り扱いに特化しており、細胞治療や遺伝子治療の安全で効率的な生産を促進しています。CDMOはまた、規制要件や技術的なハードルを乗り越え、研究から臨床応用への治療法の転換を促進することで、バイオ医薬品企業を支援しています。例えば、米国を拠点とする専門組織である米国遺伝子・細胞治療学会(ASGCT)が2023年1月に報告したところによると、遺伝子・細胞・RNA治療のパイプラインは2022年に7%の成長を遂げ、開発中の治療法は合計3,726種類にのぼる。このうち55%が遺伝子治療、22%が非遺伝子組み換え細胞治療、23%がRNA治療です。その結果、細胞治療と遺伝子治療に対する需要の高まりが、バイオロジクスCDMO市場の成長を後押ししています。

バイオロジクスCDMO市場の新興国開拓企業は、技術の進歩を活用し、バイオ医薬品の開発と製造の効率と能力を高めることを目的とした新しい細胞株などの革新的なソリューションを開発しています。これらの技術は、免疫療法の研究開発で直面する課題に対処し、より高い効力を持つ治療用抗体の生産を可能にします。例えば、2023年11月、スイスを拠点とする製薬・バイオテクノロジー分野の製造会社であるロンザ・グループは、GS Effex細胞株を発表しました。これらの細胞株は、糖分子であるフコースを100%含まない抗体を産生するように設計されており、それによって他の性能を損なうことなく効力の向上を示しています。GS Effex細胞株は、抗体治療薬の効力を増強することにより、免疫療法の研究開発における課題に対する解決策を提供します。この細胞株は安定性、拡張性、生産性を特徴としており、創薬段階から商業生産に至るまで、治療薬開発のための包括的なソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のバイオロジクスCDMO市場:細胞タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 哺乳類
  • 非哺乳類
  • 世界のバイオロジクスCDMO市場:製品タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • バイオロジクス
  • バイオシミラー

第7章 地域別・国別分析

  • 世界のバイオロジクスCDMO市場:地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界のバイオロジクスCDMO市場:国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • バイオロジクスCDMO市場:競合情勢
  • バイオロジクスCDMO市場:企業プロファイル
    • AbbVie Inc.
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • Evonik Industries AG
    • Sandoz International GmbH

第31章 その他の大手企業と革新的企業

  • ICON PLC
  • Grifols SA
  • Lonza Group Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • JSR Corp.
  • Parexel International Corporation
  • WuXi Biologics(Cayman)Inc.
  • Samsung Biologics Co. Ltd.
  • Emergent BioSolutions Inc.
  • Rentschler Biopharma SE
  • FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
  • Binex Co. Ltd.
  • Bora Pharmaceuticals Co. Ltd
  • 3P Biopharmaceuticals s.l.u

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r16782

A biologics contract development and manufacturing organization (CDMO) is a service provider that aids pharmaceutical companies in the development and manufacturing of biologic drugs. These drugs encompass a wide range of products such as vaccines, blood components, allergens, gene therapies, tissues, and recombinant therapeutic proteins.

The primary cell types utilized in biologics CDMOs are mammalian and non-mammalian cells. Mammalian cells are derived from mammals and are commonly employed in the production of biologics and cell-based therapies due to their capability to produce complex proteins and maintain post-translational modifications. The products offered typically include biologics and biosimilars.

The biologics CDMO research report is one of a series of new reports from The Business Research Company that provides biologics CDMO market statistics, including the biologics CDMO industry's global market size, regional shares, competitors with an biologics CDMO market share, detailed biologics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the biologics CDMO industry. This biologics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologics CDMO market size has grown rapidly in recent years. It will grow from $18.44 billion in 2023 to $21.30 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The expansion observed during the historical period can be attributed to several factors, including the increased focus on biologics development, cost efficiency, and flexibility offered by CDMOs, pharmaceutical companies' concentration on core competencies, adherence to regulatory compliance and quality assurance standards, as well as the globalization of pharmaceutical supply chains.

The biologics CDMO market size is expected to see rapid growth in the next few years. It will grow to $36.54 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. Anticipated growth in the forecast period can be attributed to several factors, including the increasing demand for biologic therapies, the emergence of biosimilars and bio betters, investments in biomanufacturing infrastructure, a shift towards outsourcing complex processes, a heightened focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends expected during this period encompass the expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, and the emergence of specialized CDMOs.

The escalating demand for cell and genetic therapy is poised to drive the expansion of the biologic Contract Development and Manufacturing Organization (CDMO) market in the foreseeable future. Cell and gene therapy represent cutting-edge medical modalities that harness living cells or genetic material to target underlying disease mechanisms at the cellular or genetic level, offering potential treatments for conditions that are challenging to manage or incurable using conventional pharmaceuticals. The increasing demand for cell and gene therapy stems from their potential to deliver innovative treatments for diseases by addressing fundamental genetic or cellular causes. Biologic CDMOs specialize in handling living cells, viral vectors, and genetic material, facilitating the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical hurdles, thereby facilitating the translation of therapies from research to clinical application. For example, as reported by The American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, in January 2023, the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, totaling 3,726 therapies in development. Of these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Consequently, the upsurge in demand for cell and genetic therapy is propelling the growth of the biologic CDMO market.

Leading companies in the biologic CDMO market are leveraging technological advancements to develop innovative solutions, such as new cell lines, aimed at enhancing biopharmaceutical development and manufacturing efficiency and capabilities. These technologies enable the production of therapeutic antibodies with heightened potency, addressing challenges encountered in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, introduced GS Effex cell lines. These cell lines are engineered to produce antibodies that are 100% devoid of fucose, a sugar molecule, thereby demonstrating increased potency without compromising other performance attributes. GS Effex cell lines offer a solution to challenges in immunotherapy research and development by enhancing the potency of antibody therapeutics. They are characterized by stability, scalability, and productivity, providing a comprehensive solution for therapeutic development from the discovery stage through commercial manufacturing.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based pharmaceutical organization renowned for its manufacturing and distribution of pharmaceutical products, completed the acquisition of the contract development and manufacturing organization (CDMO) assets of Eden Biologics Inc. for a total of $100 million. This strategic move aims to bolster Bora Pharmaceuticals' footprint in the global CDMO market, with a particular focus on expanding its capabilities in biologics, macromolecules, and cell and gene therapy sectors. Eden Biologics Inc., also based in Taiwan, specializes in providing contract development and manufacturing services for innovative biologics intended for therapeutic applications.

Major companies operating in the biologics cdmo market report are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biologics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologics CDMO Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologics CDMO market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologics CDMO ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics CDMO market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Cell Type: Mammalian; Non-Mammalian
  • 2) By Product Type: Biologics; Biosimilars
  • Companies Mentioned: AbbVie Inc.; Thermo Fisher Scientific Inc.; Novartis AG; Evonik Industries AG; Sandoz International GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biologics CDMO Market Characteristics

3. Biologics CDMO Market Trends And Strategies

4. Biologics CDMO Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Biologics CDMO Market Size and Growth

  • 5.1. Global Biologics CDMO Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Biologics CDMO Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Biologics CDMO Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biologics CDMO Market Segmentation

  • 6.1. Global Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Mammalian
  • Non-Mammalian
  • 6.2. Global Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biologics
  • Biosimilars

7. Biologics CDMO Market Regional And Country Analysis

  • 7.1. Global Biologics CDMO Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Biologics CDMO Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biologics CDMO Market

  • 8.1. Asia-Pacific Biologics CDMO Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biologics CDMO Market

  • 9.1. China Biologics CDMO Market Overview
  • 9.2. China Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biologics CDMO Market

  • 10.1. India Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biologics CDMO Market

  • 11.1. Japan Biologics CDMO Market Overview
  • 11.2. Japan Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biologics CDMO Market

  • 12.1. Australia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biologics CDMO Market

  • 13.1. Indonesia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biologics CDMO Market

  • 14.1. South Korea Biologics CDMO Market Overview
  • 14.2. South Korea Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biologics CDMO Market

  • 15.1. Western Europe Biologics CDMO Market Overview
  • 15.2. Western Europe Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biologics CDMO Market

  • 16.1. UK Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biologics CDMO Market

  • 17.1. Germany Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biologics CDMO Market

  • 18.1. France Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biologics CDMO Market

  • 19.1. Italy Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biologics CDMO Market

  • 20.1. Spain Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biologics CDMO Market

  • 21.1. Eastern Europe Biologics CDMO Market Overview
  • 21.2. Eastern Europe Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biologics CDMO Market

  • 22.1. Russia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biologics CDMO Market

  • 23.1. North America Biologics CDMO Market Overview
  • 23.2. North America Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biologics CDMO Market

  • 24.1. USA Biologics CDMO Market Overview
  • 24.2. USA Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biologics CDMO Market

  • 25.1. Canada Biologics CDMO Market Overview
  • 25.2. Canada Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biologics CDMO Market

  • 26.1. South America Biologics CDMO Market Overview
  • 26.2. South America Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biologics CDMO Market

  • 27.1. Brazil Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biologics CDMO Market

  • 28.1. Middle East Biologics CDMO Market Overview
  • 28.2. Middle East Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biologics CDMO Market

  • 29.1. Africa Biologics CDMO Market Overview
  • 29.2. Africa Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biologics CDMO Market Competitive Landscape And Company Profiles

  • 30.1. Biologics CDMO Market Competitive Landscape
  • 30.2. Biologics CDMO Market Company Profiles
    • 30.2.1. AbbVie Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Evonik Industries AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sandoz International GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Biologics CDMO Market Other Major And Innovative Companies

  • 31.1. ICON PLC
  • 31.2. Grifols SA
  • 31.3. Lonza Group Ltd.
  • 31.4. Boehringer Ingelheim International GmbH
  • 31.5. Catalent Inc.
  • 31.6. JSR Corp.
  • 31.7. Parexel International Corporation
  • 31.8. WuXi Biologics (Cayman) Inc.
  • 31.9. Samsung Biologics Co. Ltd.
  • 31.10. Emergent BioSolutions Inc.
  • 31.11. Rentschler Biopharma SE
  • 31.12. FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
  • 31.13. Binex Co. Ltd.
  • 31.14. Bora Pharmaceuticals Co. Ltd
  • 31.15. 3P Biopharmaceuticals s.l.u

32. Global Biologics CDMO Market Competitive Benchmarking

33. Global Biologics CDMO Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biologics CDMO Market

35. Biologics CDMO Market Future Outlook and Potential Analysis

  • 35.1 Biologics CDMO Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Biologics CDMO Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Biologics CDMO Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer